Key terms
About IKNA
Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412, and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest IKNA news
Mar 19
6:27am ET
Ikena Oncology’s IK-595: A Promising Contender in the MAPK-Driven Tumor Space
Mar 12
6:05pm ET
Ikena Oncology’s Promising Drug Pipeline Merits a Buy Rating
Mar 12
10:55am ET
Ikena Oncology’s IK-930: A Promising Contender in Targeted Oncology Treatments
Mar 12
8:07am ET
iKena Oncology expects cash to meet operating requirements into 2H26
Mar 12
8:06am ET
iKena Oncology reports Q4 EPS (41c), consensus (43c)
Feb 21
4:52pm ET
iKena Oncology CMO Sergio Santillana resigns, Caroline Germa succeeds
Feb 21
4:49pm ET
Ikena Oncology Announces Leadership Change and Strategic Shift
Jan 22
2:24pm ET
Ikena Oncology (IKNA) Gets a Buy from Wedbush
Jan 22
1:46pm ET
Buy Rating on Ikena Oncology: Undervalued Assets and Promising Pipeline in Oncology Sector
Jan 18
4:35pm ET
Ikena Oncology Inc trading resumes
Jan 18
4:21pm ET
iKena cuts 35% of workforce to focus on IK-930 and IK-595, to extend runway
Jan 18
4:00pm ET
Ikena Oncology Inc trading halted, news pending
No recent press releases are available for IKNA
IKNA Financials
Key terms
Ad Feedback
IKNA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
IKNA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
